- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06386003
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.
Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Venkat Bhat
- Phone Number: 76404 416-360-4000
- Email: venkat.bhat@utoronto.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- St. Michael's Hospital, Unity Health Toronto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
- Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
- Are willing to refrain from taking any psychiatric medications during the study period.
Exclusion Criteria:
- Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;
- Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
- Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
- Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
- History of seizure disorder;
- Uncontrolled insulin-dependent diabetes;
- Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF);
- Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;
- Lifetime history of substance-induced psychosis;
- Lifetime history of substance use disorder with a hallucinogen;
- History of alcohol use disorder in the past 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Single dose of psilocybin 25mg Massed cognitive processing therapy
|
Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and tolerability
Time Frame: Up to 16 weeks
|
Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with adverse events and responses to intervention based on qualitative data from the exit interview.
|
Up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
Time Frame: Up to 13 weeks
|
The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms.
|
Up to 13 weeks
|
Posttraumatic stress disorder Checklist-5 (PCL-5)
Time Frame: Up to 13 weeks
|
The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD.
|
Up to 13 weeks
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Up to 13 weeks
|
The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks.
Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).
|
Up to 13 weeks
|
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
Time Frame: Up to 13 weeks
|
Total score ranges from 0 to 21; a higher score denotes greater symptom severity.
|
Up to 13 weeks
|
Dissociative Experiences Scale II (DES-II)
Time Frame: Up to 13 weeks
|
The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences.
|
Up to 13 weeks
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Up to 13 weeks
|
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
|
Up to 13 weeks
|
World Health Organization Well-Being Index, 5-item (WHO-5)
Time Frame: Up to 13 weeks
|
The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.
|
Up to 13 weeks
|
Quality of relationships inventory (QRI)
Time Frame: Up to 13 weeks
|
The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true.
|
Up to 13 weeks
|
Inventory of psychosocial functioning (IPF)
Time Frame: Up to 13 weeks
|
The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days.
|
Up to 13 weeks
|
Posttraumatic Maladaptive Beliefs Scale (PMBS)
Time Frame: Up to 13 weeks
|
The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure.
|
Up to 13 weeks
|
Brief Experiential Avoidance Questionnaire (BEAQ)
Time Frame: Up to 13 weeks
|
The BEAQ is a 15-item self-report measure of experiential avoidance.
|
Up to 13 weeks
|
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
Time Frame: Up to 13 weeks
|
The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility.
|
Up to 13 weeks
|
Working Alliance Inventory- Short Form (WAI-SF)
Time Frame: Up to Day 7
|
The WAI-SF is a patient-rated measure of the alliance between a therapist and client.
|
Up to Day 7
|
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
Time Frame: Up to 13 weeks
|
The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults.
|
Up to 13 weeks
|
Self-Compassion Scale-Short Form (SCS-SF)
Time Frame: Up to 13 weeks
|
The SCS-SF is a 12-item self-report measure of self-compassion.
|
Up to 13 weeks
|
Psychological Insight Questionnaire (PIQ)
Time Frame: Up to Day 3
|
The PIQ is a 23-item self-report measure of acute experiences of insight (e.g.
awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic.
|
Up to Day 3
|
Emotional Breakthrough Inventory (EBI)
Time Frame: Up to Day 3
|
The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state.
|
Up to Day 3
|
Altered States of Consciousness Rating Scale (ASC)
Time Frame: Up to Day 3
|
The ASC measures altered states of consciousness.
|
Up to Day 3
|
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Time Frame: Up to Day 3
|
The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.
|
Up to Day 3
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect on digital physiological passive data collected through the use of a wearable device
Time Frame: Up to 16 weeks
|
Example: sleep, activity
|
Up to 16 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-230
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on Psilocybin
-
Yale UniversityHeffter Research Institute; Ceruvia Lifesciences; CH TAC LLCCompleted
-
University of Wisconsin, MadisonTRYP TherapeuticsWithdrawn
-
Yale UniversityCeruvia LifesciencesCompleted
-
King's College LondonUniversity of CambridgeRecruitingAutism Spectrum DisorderUnited Kingdom
-
Yale UniversityHeffter Research InstituteActive, not recruitingMajor Depressive DisorderUnited States
-
Section for Affective Disorders; Northern Stockholm...Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...Recruiting
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Yale UniversityTerminated
-
University of Colorado, DenverEnrolling by invitationAnhedonia | Major Depressive Disorder | Treatment Resistant DepressionUnited States
-
Multidisciplinary Association for Psychedelic StudiesWithdrawnAnxiety | Stage IV MelanomaUnited States